Literature DB >> 24601977

The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.

Susan I Vear1, Gregory D Ayers, Sara L Van Driest, Robert F Sidonio, Charles Michael Stein, Richard H Ho.   

Abstract

The influence of genetic variation on warfarin dose requirement is limited for paediatric patients. We performed a retrospective, cross-sectional study to examine the effect of variant CYP2C9 and VKORC1 genotypes on warfarin dose in 100 children. Those with VKORC1 genotype AA required 48% of the dose of homozygous wild-type (GG, P < 0·0001). Patients with any variant CYP2C9 allele required 71% of the dose for wild-type (P = 0·001). The effect of variant VKORC1 alleles tended to vary with age, suggesting developmental ontogeny may influence warfarin sensitivity. Age, CYP2C9 genotype, VKORC1 genotype and age:VKORC1 interaction accounted for 53% of warfarin dose variability.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  CYP2C9; VKORC1; paediatrics; pharmacogenomics; warfarin

Mesh：

Substances：

Year:  2014        PMID： 24601977      PMCID： PMC4043918          DOI： 10.1111/bjh.12817

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  15 in total

1.  Immunoquantification of epoxide hydrolase and cytochrome P-450 isozymes in fetal and adult human liver microsomes.

Authors:  T Cresteil; P Beaune; P Kremers; C Celier; F P Guengerich; J P Leroux
Journal:  Eur J Biochem       Date:  1985-09-02

2.  VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

Authors:  Tina T Biss; Peter J Avery; Leonardo R Brandão; Elizabeth A Chalmers; Michael D Williams; John D Grainger; Julian B S Leathart; John P Hanley; Ann K Daly; Farhad Kamali
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

3.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Authors:  Mark J Rieder; Alexander P Reiner; Brian F Gage; Deborah A Nickerson; Charles S Eby; Howard L McLeod; David K Blough; Kenneth E Thummel; David L Veenstra; Allan E Rettie
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

4.  In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.

Authors:  Ulrike Nowak-Göttl; Kevin Dietrich; Daria Schaffranek; Noha Sharaf Eldin; Yutaka Yasui; Christof Geisen; Lesley G Mitchell
Journal:  Blood       Date:  2010-09-10       Impact factor: 22.113

Review 5.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Authors:  J A Johnson; L Gong; M Whirl-Carrillo; B F Gage; S A Scott; C M Stein; J L Anderson; S E Kimmel; M T M Lee; M Pirmohamed; M Wadelius; T E Klein; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-09-07       Impact factor: 6.875

Review 6.  Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle.

Authors:  Johannes Oldenburg; Carville G Bevans; Clemens R Müller; Matthias Watzka
Journal:  Antioxid Redox Signal       Date:  2006 Mar-Apr       Impact factor: 8.401

Review 7.  Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis.

Authors:  Limei Yang; Weihong Ge; Feng Yu; Huaijun Zhu
Journal:  Thromb Res       Date:  2009-11-25       Impact factor: 3.944

8.  VKORC1 pharmacogenomics summary.

Authors:  Ryan P Owen; Li Gong; Hersh Sagreiya; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

9.  Warfarin pharmacogenomics in children.

Authors:  Susan I Vear; C Michael Stein; Richard H Ho
Journal:  Pediatr Blood Cancer       Date:  2013-05-16       Impact factor: 3.167

10.  Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Paul Monagle; Elizabeth Chalmers; Anthony Chan; Gabrielle deVeber; Fenella Kirkham; Patricia Massicotte; Alan D Michelson
Journal:  Chest       Date:  2008-06       Impact factor: 9.410
View more
  6 in total

1.  The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development.

Authors:  Joshua C Denny; Sara L Van Driest; Wei-Qi Wei; Dan M Roden
Journal:  Clin Pharmacol Ther       Date:  2018-02-05       Impact factor: 6.875

2.  Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models.

Authors:  Elizabeth Marek; Jeremiah D Momper; Ronald N Hines; Cheryl M Takao; Joan C Gill; Vera Pravica; Andrea Gaedigk; Gilbert J Burckart; Kathleen A Neville
Journal:  J Pediatr Pharmacol Ther       Date:  2016 May-Jun

Review 3.  Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children.

Authors:  Frederique Rodieux; Melanie Wilbaux; Johannes N van den Anker; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

4.  Considerations for Implementing Precision Therapeutics for Children.

Authors:  Matthew J McLaughlin; Jonathan Wagner; Valentina Shakhnovich; Bruce Carleton; J Steven Leeder
Journal:  Clin Transl Sci       Date:  2019-01-25       Impact factor: 4.689

5.  Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.

Authors:  Masanobu Takeuchi; Tohru Kobayashi; Leonardo R Brandão; Shinya Ito
Journal:  Syst Rev       Date:  2016-06-23

Review 6.  Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.

Authors:  Hedy Maagdenberg; Susanne J H Vijverberg; Marc B Bierings; Bruce C Carleton; Hubertus G M Arets; Anthonius de Boer; Anke H Maitland-van der Zee
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.